MHRA Medical Device Alert: Check UKCA and CE Marks

In a new safety alert, the Medicines and Healthcare products Regulatory Agency, or MHRA, is telling healthcare professionals to stop using and supplying a group of medical devices that reached the UK market without the right conformity markings. If you work in a hospital, clinic, procurement team or distribution chain, the immediate message is simple: pause, check stock, and do not pass these devices on. This is not because the MHRA says it has found a known defect. The agency says it has not identified a specific performance problem, quality issue or safety signal with the products. The concern is different. These devices do not have the appropriate markings and supporting certification required for legal supply in the UK, which means regulators cannot give the usual reassurance that they meet expected standards for quality, safety and sterility.

If the phrase conformity marking sounds technical, it helps to slow it down. In plain English, a UKCA or CE mark is a sign that a device has been through the checks, paperwork and certification needed for legal supply. It is not just a logo printed on a box. It points to an assessment process that should show whether a product meets the rules designed to protect patients and staff. The MHRA links this alert to the UK Medical Devices Regulations 2002 and the EU Medical Devices Regulation 2017/745. You do not need to memorise those titles to understand the main point. When a device is missing the correct marking, or the certification behind it is not right, the system cannot confirm that the product has cleared the standard required for the UK market.

The affected products are not rare specialist items that sit untouched on a shelf. They include devices used in everyday clinical work for blood collection and infusion, surgical and biopsy procedures, wound care and skin preparation. That matters because these are the sorts of products teams may reach for quickly in routine care. According to the MHRA notice, the products are the VAKU-8 Blood Collection / Infusion / Scalp Vein Set from Hindustan Syringes & Medical Devices Ltd, Bipson’s Gauze Swab Sterile from Bipson Surgical Private Ltd, the Technocut Scalpel from Niraj Industries Ltd, Romsons Alco Swabs from Romsons Group Private Ltd, the Medi Grip Adhesive Bandage (Antiseptic) from Precision Coatings (P) Ltd, and the Bone Marrow Biopsy Needle from Meditech Devices Pvt. Ltd.

**What this means:** a regulator can say there is no identified defect and still tell you to stop using a product. That may sound confusing at first, but it is a normal part of how safety systems work. Regulation is not only about reacting after harm appears. It is also about making sure the right checks happened before a device was ever supplied. In this case, the missing reassurance is the issue. Because the correct conformity assessment was not in place for supply in the UK, there is not enough evidence to confirm that these devices meet the required standards. In healthcare, that gap is serious enough on its own to justify quarantine.

For healthcare organisations, the next step is practical rather than theoretical. Check whether any of the affected devices are currently in use, sitting in storage, or available for supply. If you find them, stop using them immediately, stop supplying them, place any remaining stock in quarantine, and move to compliant alternatives. Here, quarantine means setting the stock aside so it cannot be used or redistributed by mistake. The MHRA says affected devices should be retained while organisations wait for further advice. The agency has also published a Device Safety Information notice, reference DSI/2026/007, with images of the products and further detail to help teams identify what they are looking at.

If your organisation thinks it has received, supplied or distributed any of these products, the MHRA says it should notify the agency straight away at devices.compliance@mhra.gov.uk and quote DSI/2026/007. If you know where the products were sent next, that onward distribution information should be shared too. This is how traceability works in practice: the regulator needs to know where stock has travelled so it can be found and contained. Distributors have been told to stop any further supply and to help with traceability work if asked. Healthcare professionals are also being advised to report suspected or actual adverse incidents through the reporting arrangements used in their region. The MHRA also points readers to its medical device guidance for patients and users for help with identifying compliant devices and using them safely.

There is a wider lesson here for anyone trying to make sense of medical device regulation. A conformity mark is not decorative and it is not optional. It is one of the visible ways the safety system shows that a device is backed by assessment, certification and accountability before it reaches patients. For readers outside healthcare, this is a useful reminder that many safety alerts are about preventing uncertainty from turning into harm. For readers inside healthcare, the message is sharper: if the markings or certification are not right, routine use is not a good enough reason to carry on. Stop, verify, quarantine, and use a compliant alternative.